Physician profile
Thomas E Talkie
NPI 1558353409
$2,074.17
in general payments reported to CMS, 2019-2025
13 companies · $99.44 in 2025
The $99.44 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $100 · 2021: $89.69 · 2022: $234 · 2023: $792 · 2024: $625 · 2025: $99.44.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,420 · Entertainment: $96.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,419.56 |
| Entertainment | $96.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Vision Care, INC. | $469.48 | 2020-2024 | Acuvue |
| Bausch & Lomb Americas INC. | $305.78 | 2022-2023 | Vyzulta, Lotemax Sm |
| Alcon Vision LLC | $300.68 | 2023-2024 | Total30 |
| Glaukos Corporation | $136.79 | 2024 | Ce-Marked Kxla System |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $134.16 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $125.00 | 2022 | |
| Abbvie INC. | $100.00 | 2024 | |
| Lkc Technologies, INC. | $99.44 | 2025 | |
| Optos, INC. | $96.89 | 2023 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Sun Pharmaceutical Industries INC. | $95.76 | 2023 | Cequa |
| Oyster Point Pharma, INC. | $90.39 | 2023 | Tyrvaya |
| Dompe US, INC. | $85.50 | 2024 | Oxervate |
| Coopervision INC. | $34.30 | 2023 | Misight Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Talkie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.